Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO Study

Conclusions: QoL was maintained during the everolimus therapy and limitations as well as time effort were acceptable for most of the patients. The study supports previous findings on switching mode of action after anti-VEGFR-targeted therapy to a mammalian target of rapamycin inhibitor.Oncol Res Treat

https://www.karger.com/Article/FullText/494278

Source: Oncology Research and Treatment - January 18, 2019 Category: Cancer & Oncology Source Type: research